Cardiff Oncology Stock Market Value
| CRDF Stock | USD 2.61 0.07 2.76% |
| Symbol | Cardiff |
Cardiff Oncology Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiff Oncology. If investors know Cardiff will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiff Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.95) | Revenue Per Share 0.015 | Quarterly Revenue Growth 0.17 | Return On Assets (0.38) | Return On Equity (0.68) |
The market value of Cardiff Oncology is measured differently than its book value, which is the value of Cardiff that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiff Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cardiff Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiff Oncology's market value can be influenced by many factors that don't directly affect Cardiff Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiff Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiff Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiff Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cardiff Oncology 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Cardiff Oncology's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Cardiff Oncology.
| 11/01/2024 |
| 12/01/2024 |
If you would invest 0.00 in Cardiff Oncology on November 1, 2024 and sell it all today you would earn a total of 0.00 from holding Cardiff Oncology or generate 0.0% return on investment in Cardiff Oncology over 30 days. Cardiff Oncology is related to or competes with Reviva Pharmaceuticals, PDS Biotechnology, Reviva Pharmaceuticals, Cognition Therapeutics, Transcode Therapeutics, Kodiak Sciences, and Sellas Life. Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California More
Cardiff Oncology Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Cardiff Oncology's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Cardiff Oncology upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 7.32 | |||
| Information Ratio | 0.0399 | |||
| Maximum Drawdown | 41.21 | |||
| Value At Risk | (8.03) | |||
| Potential Upside | 9.48 |
Cardiff Oncology Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cardiff Oncology's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Cardiff Oncology's standard deviation. In reality, there are many statistical measures that can use Cardiff Oncology historical prices to predict the future Cardiff Oncology's volatility.| Risk Adjusted Performance | 0.0577 | |||
| Jensen Alpha | 0.1951 | |||
| Total Risk Alpha | (0.60) | |||
| Sortino Ratio | 0.0311 | |||
| Treynor Ratio | 0.2834 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cardiff Oncology's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Cardiff Oncology Backtested Returns
Cardiff Oncology appears to be very risky, given 3 months investment horizon. Cardiff Oncology secures Sharpe Ratio (or Efficiency) of 0.0773, which signifies that the company had a 0.0773% return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Cardiff Oncology, which you can use to evaluate the volatility of the firm. Please makes use of Cardiff Oncology's Risk Adjusted Performance of 0.0577, mean deviation of 3.82, and Downside Deviation of 7.32 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Cardiff Oncology holds a performance score of 6. The firm shows a Beta (market volatility) of 1.25, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cardiff Oncology will likely underperform. Please check Cardiff Oncology's semi variance, rate of daily change, and the relationship between the value at risk and kurtosis , to make a quick decision on whether Cardiff Oncology's price patterns will revert.
Auto-correlation | -0.42 |
Modest reverse predictability
Cardiff Oncology has modest reverse predictability. Overlapping area represents the amount of predictability between Cardiff Oncology time series from 1st of November 2024 to 16th of November 2024 and 16th of November 2024 to 1st of December 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Cardiff Oncology price movement. The serial correlation of -0.42 indicates that just about 42.0% of current Cardiff Oncology price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.42 | |
| Spearman Rank Test | 0.07 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Cardiff Oncology lagged returns against current returns
Autocorrelation, which is Cardiff Oncology stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Cardiff Oncology's stock expected returns. We can calculate the autocorrelation of Cardiff Oncology returns to help us make a trade decision. For example, suppose you find that Cardiff Oncology has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Cardiff Oncology regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Cardiff Oncology stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Cardiff Oncology stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Cardiff Oncology stock over time.
Current vs Lagged Prices |
| Timeline |
Cardiff Oncology Lagged Returns
When evaluating Cardiff Oncology's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Cardiff Oncology stock have on its future price. Cardiff Oncology autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Cardiff Oncology autocorrelation shows the relationship between Cardiff Oncology stock current value and its past values and can show if there is a momentum factor associated with investing in Cardiff Oncology.
Regressed Prices |
| Timeline |
Currently Active Assets on Macroaxis
When determining whether Cardiff Oncology is a strong investment it is important to analyze Cardiff Oncology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cardiff Oncology's future performance. For an informed investment choice regarding Cardiff Stock, refer to the following important reports:Check out Cardiff Oncology Correlation, Cardiff Oncology Volatility and Cardiff Oncology Alpha and Beta module to complement your research on Cardiff Oncology. For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Cardiff Oncology technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.